期刊文献+

左氧氟沙星药代动力学/药效动力学参数与金黄色葡萄球菌耐药的相关性研究 被引量:25

Correlation of levofloxacin pharmacokinetic/pharmacodynamic parameters with selection of staphylococcus aureus resistance
暂未订购
导出
摘要 目的:探讨左氧氟沙星药代动力学/药效动力学(PK/PD)参数与金黄色葡萄球菌耐药的相关性。方法:建立兔组织笼金黄色葡萄球菌感染模型,给予不同剂量的左氧氟沙星灌胃治疗。抽取组织笼内组织液进行药代动力学测定,计算PK/PD参数,同时监测组织笼内细菌药物敏感性变化。结果:PK/PD参数AUC24/MIC、AUC24/MPC、Cmax/MIC、Cmax/MPC、T>MPC和Tmsw和耐药发生相关(MIC:最小抑菌浓度,MPC:防耐药变异浓度,MSW:耐药突变选择窗),T>MIC与耐药的发生无相关性。当AUC24/MIC在20~150h时,容易发生耐药,保持药物AUC24/MPC>25h可以限制耐药的发生。体内MSW的上、下限分别为AUC24/MPC=25h和AUC24/MIC=20h。结论:AUC24/MPC、Cmax/MPC和T>MPC可能是预测耐药发生的独立参数。 AIM:To study the correlation of levofloxacin pharmacokinetic/pharmacodynamic parameters with selection of staphylococcus aureus resistance.METHODS:Tissue cage infection model with staphylococcus aureus was established in rabbits,and the infected animals were given levofloxacin intragastrically at various doses.Changes in levofloxacin concentration,levofloxacin susceptibility of bacteria were monitored at the site of infection.RESULTS:AUC24/MIC,AUC24/MPC,Cmax/MIC,Cmax/MPC,time above MPC and Tmsw showed a statistically significant correlation with selection of staphylococcus aureus resistance,and time above MIC did not(MIC:minimal inhibitory concentration,MPC:mutant prevention concentration,MSW:mutant selection window).Loss of bacterial susceptibility occurred easily when AUC24/MIC was between 20 h and 150 h,and keeping AUC24/MPC above 25 h could restrict selection of resistance.The upper boundary of the selection window in vivo was estimated as an AUC24/MPC value of 25 h,and the lower boundary was estimated as an AUC24/MIC value of 20 h.CONCLUSION:AUC24/MPC,Cmax/MPC and time above MPC may be the parameters for predicting resistance.
出处 《中国临床药理学与治疗学》 CAS CSCD 2007年第9期989-992,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 国家自然科学基金资助项目(30370615 30672505)
关键词 左氧氟沙星 药代动力学/药效动力学 金黄色葡萄球菌 耐药突变选择窗 levofloxacin pharmacokinetic/pharmacodynamic staphylococcus aureus mutant selection window
  • 相关文献

参考文献12

  • 1Craig WA.Pharmacokinetic/Pharmacyodynamic parameters:rationale for antibacterial dosing of mice and men[J].Clin Infect Dis,1998;26:1-10.
  • 2Forrest A,Nix D,Ballow C,et al.Pharmacodynamic of intravennous ciprofloxacin in seriously ill patients[J].Antimicrob Agents Chemother,1993;37:1073-1081.
  • 3Dong Y,Zhao X,Domagala J,et al.Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus[J].Antimicrob Agents Chemother,1999;43:1756-1758.
  • 4Zhao X,Drlica K.Restricting the selection of antibiotic-resistant mutants:a general strategy derived from fluoroquinolones studies[J].Clin Infect Dis,2001;33:S147-S156.
  • 5崔俊昌,刘又宁,王睿,梁蓓蓓,裴斐,郑专杰.4种氟喹诺酮类药物对金黄色葡萄球菌的防耐药变异浓度[J].中华医学杂志,2004,84(22):1863-1866. 被引量:34
  • 6崔俊昌,刘又宁,王睿杭,童卫杭,李朝霞.左氧氟沙星对兔组织笼金黄色葡萄球菌感染的疗效研究[J].中国临床药理学与治疗学,2007,12(3):291-294. 被引量:7
  • 7童卫杭,柴栋,崔俊昌,陈锟,王睿.兔感染性模型组织液中左氧氟沙星浓度HPLC测定[J].中国抗生素杂志,2005,30(12):759-761. 被引量:6
  • 8Drlica K,Zhao X,Blondeau JM,et al.Low correlation between MIC and mutant prevention concentration[J].Antimicrob Agents Chemother,2006;50:403-404.
  • 9Ofofsson FK,Marcusson LL,Komp Lindgren P,et al.Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model:relation between drug exposure and mutant prevention concentration[J].J Antimicrob Chemother,2006;57:1116-1121.
  • 10Allen GP,Kaatz GW,Rybak MJ.In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model[J].Int J Antimicrob Agents,2004;24:150-160.

二级参考文献16

  • 1孙春华,李可欣,曹国颖,于京建.健康受试者口服Levofloxacin的药动学研究[J].中国药房,1995,6(6):23-24. 被引量:8
  • 2李朝霞,刘又宁,王睿,崔俊昌,程仕虎,童卫杭.氟喹诺酮类药物对金黄色葡萄球菌及其耐药突变体的耐药性研究[J].中国临床药理学与治疗学,2006,11(6):696-701. 被引量:17
  • 3Fernandez J,Barrett J F,Licata L,et al.Comparison of efficacies of levofloxacin andoral coiprofloxacin in a rabbit model of a staphylococcal abscess [J].Antimicrob Agents Chemother,1999,43:667.
  • 4Goodwin S D,Gallis H A,Choro A T,et al.Pharmaco ki netics and safety of levofloxacin in patients with human immunodeficiency virus infection [J].Antimicrob Agents Chemoth,1994,38 (4):799.
  • 5Tanaka K,Iwamoto M,Maesaki S,et al.Laboratory and clinical studies on levofloxacin [J].Jpn J Antibiot,1992,45(5):548.
  • 6Stein GE.Pharmacokinetics and pharmacodynamics of newer fluoroquinolones[J].Clin Infect Dis,1996;23(Supple 1):S19-S24.
  • 7Aminimanizani A,Beringer P,Jelliffe R.Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials[J].Clin Pharmacokinet,2001;40:169-187.
  • 8Fernandez J,Barrett JF,Licata L,et al.Comparison of efficacies of oral levofloxacin and oral ciprofloxacin in a rabbit model of a staphylococcal abscess[J].Antimicrob Agents Chemother,1999;43:667-671.
  • 9Xuan D,Zhong M,Mattoes H,et al.Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model[J].Antimicrob Agents Chemother,2001;45:794-799.
  • 10Davidson R,Cavalcanti R,Brunton JL,et al.Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia[J].N Engl J Med,2002;346:747-750.

共引文献41

同被引文献318

引证文献25

二级引证文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部